Biotechnology

Eligo Publishes in Nature a Landmark Study That Unlocks Genome Editing of Bacteria in the Gut

PARIS, July 10, 2024 /PRNewswire/ -- For the first time, a team of scientists at Eligo has demonstrated it was possible to genetically modify bacteria with nearly 100% efficiency directly in the gut of animals. This work provides scientists with a novel strategy to better understand how genes fro...

2024-07-10 23:00 1771

WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year

SHANGHAI, July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been named as a constituent company of the FTSE4Good Index Series. This marks the fourth consecutive year t...

2024-07-10 13:30 3462

3D Artificial Cornea from Stem Cells: Chula Researchers Advance Canine Corneal Wound Treatment

BANGKOK, July 10, 2024 /PRNewswire/ -- Chulalongkorn University's Faculty of Veterinary Science and the Faculty of Engineering have worked together to research and develop a three-dimensional artificial cornea from stem cells that offers a way to treat deep corneal wounds in dogs. The innovation ...

2024-07-10 09:00 2592

KOSÉ, I Peace, and Reju Enter Strategic Partnership to Develop Personalized Beauty Products Based on iPS Cells

Demonstration testing of "my own" beauty products PALO ALTO, Calif., July 9, 2024 /PRNewswire/ -- KOSÉ Corporation (Headquarters: Chuo-ku,Tokyo; President: Kazutoshi Kobayashi), I Peace, Inc. (Headquarters:Palo Alto, California, USA; Founder & CEO: Koji Tanabe), and Reju, Inc. (Headquarters: Min...

2024-07-09 23:00 2093

Alteogen Receives Ministry of Food and Drug Safety (MFDS) Approval for Tergase®

* Tergase® poised to capture a fair share of the global hyaluronidase market. DAEJEON, South Korea, July 8, 2024 /PRNewswire/ -- Alteogen Inc.  (KOSDAQ:196170) announced that the Ministry of Food and Drug Safety (MFDS) of Korea approved its New Drug Application (NDA...

2024-07-08 21:00 2071

MGI Tech Partners with Australian Research Council Training Centre CEAStAR to Lead Innovation in Antimicrobial Resistance Solutions

BRISBANE, Australia, July 8, 2024 /PRNewswire/ -- MGI Australia Pty Ltd, subsidiary of MGI Tech Co., Ltd., a company committed to building core tools and technologies that drive innovation in life science, proudly announces its strategic partnership with TheUniversity of Queensland(UQ) led Centre...

2024-07-08 17:14 2429

Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors

MORRISVILLE, NC., July 8, 2024 /PRNewswire/ -- Immorna Biotherapeutics, Inc. (Immorna), a clinical stage biotechnology company developing both self-replicating and conventional mRNA-based therapeutics and vaccines, announced today that the U.S. Food and Drug Administration (FDA) has cleared its ...

2024-07-08 16:28 1509

Sirnaomics Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Therapeutics

HONG KONG and GERMANTOWN, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or " Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, to...

2024-07-08 14:30 2236

Olverembatinib Approved for Commercialization in Macau China

ROCKVILLE, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies for hematological malignancies, announced today that its novel BCR-ABL1 tyro...

2024-07-08 08:55 2084

XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO® has now received approval as a monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) marking the second approved indication of ...

2024-07-05 21:18 6577

Hinova Pharmaceuticals receives FDA Fast Track Designation for HP518 for Treatment of AR+ Triple-Negative Breast Cancer (TNBC)

CHENGDU, China, July 5, 2024 /PRNewswire/ -- Hinova Pharmaceuticals Inc. (688302.SH), a leading biopharmaceutical company dedicated to developing innovative cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for HP518, an investi...

2024-07-05 21:00 4786

LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition

GAITHERSBURG, Md., July 5, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for in...

2024-07-05 19:00 5072

IASO Bio and Innovent Enhance Strategic Collaboration in Cell Therapy

SHANGHAI and NANJING, China and SAN JOSE, Calif., July 5, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing, and marketing innovative cell therapies and antibody products, and Innovent Biologics, Inc. ("Innovent", H...

2024-07-05 16:30 4190

Innovent and IASO Bio Enhance Strategic Collaboration in Cell Therapy

SAN FRANCISCO and SUZHOU, China, July 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic,...

2024-07-05 16:30 4795

Biostar Pharma Announces FDA Clearance of the IND Application for a Phase 2 Study of Utidelone Injection (UTD1) in HER2- Breast Cancer Brain Metastasis

SAN FRANCISCO, July 5, 2024 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Biostar), which is a synthetic biology-driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that ...

2024-07-05 16:07 1522

Zhejiang Doer Biologics Completes Enrollment of the Phase 1b/2a Trial Evaluating DR10624 in Obese Subjects with Modest Hypertriglyceridemia

HANGZHOU, China, July 5, 2024 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that the company has completed the enrollment in the Phase1b/2a trial ...

2024-07-05 15:56 3509

LOTTE BIOLOGICS Holds Groundbreaking for Songdo Bio Campus

* Plans to Join the Ranks of the TOP 10 Global CDMOs, Heralding a New Era in the Global CDMO Landscape SEOUL, South Korea, July 3, 2024 /PRNewswire/ -- In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEORichard W. Lee...

2024-07-04 11:17 2551

Ascentage Pharma Received US$100 Million Option Payment from Takeda

ROCKVILLE, Md. and SUZHOU, China, July 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that onJuly 2, 2024,...

2024-07-04 08:28 4404

/C O R R E C T I O N -- Menarini Silicon Biosystems/

In the news release, Menarini's cell based non-invasive prenatal technology demonstrates high resolution detection of fetal genomic abnormalities from a simple maternal blood draw, issued02-Jul-2024 by Menarini Silicon Biosystems over PR Newswire, we are advised by the company that the subheadlin...

2024-07-03 03:24 2983

Bloomage Ranks on World Brand Lab's China 500 Most Valuable Brands List

PARSIPPANY, N.J., July 2, 2024 /PRNewswire/ -- Bloomage has once again ranked on the "China's 500 Most Valuable Brands" list by World Brand Lab, a premier global brand value evaluation agency. This milestone not only affirms the strength of Bloomage's brand but also recognizes its long-term commi...

2024-07-02 21:00 1572
1 ... 31323334353637 ... 311